In an industry riddled with disappointing data, regulatory setbacks and a depressing 90 percent-plus failure rate, biotech companies have learned to be resilient, raising money whenever possible – and sometimes when it almost isn't – and often reinventing themselves in the wake of disastrous pipeline flops.